Bone marrow angiogenesis: Methods of quantification and changes evolving in chronic myeloproliferative disorders

Histology and Histopathology

Volumn 19, Issue 4, 2004, Pages 1245-1260

  Kvasnicka, H M ^a   Thiele, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

3D reconstruction; Angiogenesis; Chronic myeloproliferative disorders; Microvessel density; Myelofibrosis; Sinusoidal architecture

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CD34 ANTIGEN; CELL MARKER; CYTOKINE; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE;

ANALYTIC METHOD; ANGIOGENESIS; BLOOD FLOW; BLOOD VESSEL COMPLIANCE; BONE MARROW; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DENSITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; ERYTHROCYTE AGGREGATION; FIBER; HUMAN; IDIOPATHIC DISEASE; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; MICROVASCULARIZATION; MORPHOMETRICS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; PERFUSION; POLYCYTHEMIA VERA; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; SCLEROSIS; THREE DIMENSIONAL IMAGING; THROMBOCYTHEMIA; TREATMENT FAILURE; VASCULAR DISEASE; VASCULARIZATION;

BONE MARROW; CHRONIC DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICROCIRCULATION; MODELS, ANATOMIC; MODELS, BIOLOGICAL; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 6344282804     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Abboud C.N. (1995). Human bone marrow microvascular endothelial cells: elusive cells with unique structural and functional properties. Exp. Hematol. 23, 1-3.
2. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E., Thomas D., Koller C., Estrov Z., O'Brien S., Keating M., Freireich E. and Albitar M. (2000). Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96, 2240-2245.
3. Aguayo A., Giles F. and Albitar M. (2003). Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk. Lymphoma 44, 213-222.
4. Akagi K., Ikeda Y., Sumiyoshi Y., Kimura Y., Kinoshita J., Miyazaki M. and Abe T. (2002). Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development. Surgery 131, 109-113.
5. Albitar M. (2001). Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 106, 170-176.
6. Apaja-Sarkkinen M., Autio-Harmainen H., Alavaikko M., Risteli J. and Risteli L. (1986). Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br. J. Haematol. 63, 571-580.
7. Barosi G., Grossi A., Comotti B., Musto P., Gamba G. and Marchetti M. (2001). Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 114, 78-83.
8. Bauer J.A., Morrison B.H., Grane R.W., Jacobs B.S., Borden E.C. and Lindner D.J. (2003). IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J. Interferon Cytokine Res. 23, 3-10.
9. Beham-Schmid C., Apfelbeck U., Sill H., Tsybrovsky O., Hofler G., Haas O.A. and Linkesch W. (2002). Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99, 381-383.
10. Bellamy W.T., Richter L., Frutiger Y. and Grogan T.M. (1999). Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59, 728-733.
11. Beranek J.T. (2001). Antiangiogenesis in hematologic diseases. Ann. Hematol. 80, 251-252.
12. Berse B., Hunt J.A., Diegel R.J., Morganelli P., Yeo K., Brown F. and Fava R.A. (1999). Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1γ-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol. 115, 176-182.
13. Bertolini F., Mancuso P., Gobbi A. and Pruneri G. (2000). The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp. Hematol. 28, 993-1000.
14. Bock O., Schlue J., Lehmann U., von Wasielewski R., Langer F. and Kreipe H. (2002). Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression. Blood 100, 2274-2275.
15. Bonn D. (2003). Thalidomide: no benefit in myelofibrosis with myeloid metaplasia. Lancet Oncol 4, 70.
16. Bossi P., Viale G., Lee A.K., Alfano R., Coggi G. and Bosari S. (1995). Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res. 55, 5049-5053.
17. Brun M., Bourdoulous S., Couraud P.O., Elion J., Krishnamoorthy R. and Lapourneroulie C. (2003). Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. Pharmacogenomics J. 3, 215-226.
18. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J. and Lydon N.B. (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145.
19. Buchdunger E., O'Reilly T. and Wood J. (2002). Pharmacology of imatinib (STI571). Eur. J. Cancer 38 Suppl 5, S28-36.
20. Canepa L., Ballerini F., Varaldo R., Quintino S., Reni L., Clavio M., Miglino M., Pierri I. and Gobbi M. (2001). Thalidomide in agnogenic and secondary myelofibrosis. Br. J. Haematol. 115, 313-315.
21. Carmeliet P. and Jain R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
22. Charbord P. (1986). Increased vascularity of bone marrow in myelofibrosis. Br. J. Haematol. 62, 595-596.
23. D'Amato R.J., Loughnan M.S., Flynn E. and Folkman J. (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91, 4082-4085.
24. De Bont E.S., Rosati S., Jacobs S., Kamps W.A. and Vellenga E. (2001). Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br. J. Haematol. 113, 296-304.
25. Di Raimondo F., Azzaro M.P., Palumbo G., Bagnato S., Giustolisi G., Floridia P., Sortino G. and Giustolisi R. (2000a). Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 85, 800-805.
26. Di Raimondo F., Palumbo G.A., Azzaro M.P. and Giustolisi R. (2000b). Angiogenesis in acute myeloid leukemia. Blood 96, 3656-3657.
27. Di Raimondo F., Palumbo G.A., Molica S. and Giustolisi R. (2001). Angiogenesis in chronic myeloproliferative diseases. Acta Haematol. 106, 177-183.
28. Dickson D.J. and Shami P.J. (2001). Angiogenesis in acute and chronic leukemias. Leuk. Lymphoma 42, 847-853.
29. Donovan D., Harmey J.H., Toomey D., Osborne D.H., Redmond H.P. and Bouchier-Hayes D.J. (1997). TGF beta-1 regulation of VEGF production by breast cancer cells. Ann. Surg. Oncol. 4, 621-627.
30. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S. and Sawyers C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
31. Ebos J.M., Tran J., Master Z., Dumont D., Melo J.V., Buchdunger E. and Kerbel R.S. (2002). Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol. Cancer Res. 1, 89-95.
32. Elliott M.A., Mesa R.A., Li C.Y., Hook C.C., Ansell S.M., Levitt R.M., Geyer S.M. and Tefferi A. (2002). Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 117, 288-296.
33. Ferrara N. (1996). Vascular endothelial growth factor. Eur. J. Cancer 32A, 2413-2422.
34. Ferrara N. (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14.
35. Ferrara N. and Gerber H.P. (2001). The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 106, 148-156.
36. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M. and Hossfeld D.K. (1997). Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89, 1870-1875.
37. Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
38. Fox S.B. (1997). Tumour angiogenesis and prognosis. Histopathology 30, 294-301.
39. Fox S.B., Leek R.D., Weekes M.P., Whitehouse R.M., Gatter K.C. and Harris A.L. (1995). Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J. Pathol. 177, 275-283.
40. Garland J.M., Kumar S. and Heagerty A. (2000). Angiogenesis in chronic myelogenous leukaemia. Lancet 356, 1026-1027.
41. Georgii A., Buesche G. and Kreft A. (1998). The histopathology of chronic myeloproliferative diseases. Baillieres Clin. Haematol. 11, 721-749.
42. Giles F.J. (2001). The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 6 (Suppl 5), 32-39.
43. Glade-Bender J., Kandel J.J. and Yamashiro D.J. (2003). VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol Ther. 3, 263-276.
44. Guidi A.J., Berry D.A., Broadwater G., Perloff M., Norton L., Barcos M.P. and Hayes D.F. (2000). Association of angiogenesis in lymph node metastases with outcome of breast cancer. J. Natl. Cancer Inst. 92, 486-492.
45. Hanahan D. and Folkman J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
46. Hansen S., Grabau D.A., Rose C., Bak M. and Sorensen F.B. (1998). Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab. Invest. 78, 1563-1573.
47. Hasselbalch H.C. (2001). A possible role for STI571 in the treatment of idiopathic myelofibrosis. Am. J. Hematol. 68, 63-64.
48. Hehlmann R., Hochhaus A., Berger U. and Reiter A. (2000). Current trends in the management of chronic myelogenous leukemia. Ann. Hematol. 79, 345-354.
49. Hussong J.W., Rodgers G.M. and Shami P.J. (2000). Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95, 309-313.
50. Imbert M., Pierre R., Thiele J., Vardiman J.W., Brunning R.D. and Flandrin G. (2001). Essential thrombocythaemia. In WHO Classification of Tumours: Tumours of haematopoietic and lymphoid tissues. Jaffe E.S., Harris N.L., Stein H. and Vardiman J.W. (eds) IARC Press. Lyon. pp. 39-41.
51. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M. and Morra E. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652.
52. Kantarjian H.M., O'Brien S., Cortes J.E., Shan J., Giles F.J., Rios M.B., Faderl S.H., Wierda W.G., Ferrajoli A., Verstovsek S., Keating M.J., Freireich E.J. and Talpaz M. (2003). Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97, 1033-1041.
53. Kenyon B.M., Browne F. and D'Amato R.J. (1997). Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 64, 971-978.
54. Kini A.R., Kay N.E. and Peterson L.C. (2000). Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14, 1414-1418.
55. Kini A.R., Peterson L.A., Tallman M.S. and Lingen M.W. (2001). Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 97, 3919-3924.
56. Korkolopoulou P., Konstantinidou A.E., Kavantzas N., Patsouris E., Pavlopoulos P.M., Christodoulou P., Thomas-Tsagli E. and Davaris P. (2001). Morphometric microvascular characteristics predict prognosis in superficial and invasive bladder cancer. Virchows Arch. 438, 603-611.
57. Korkolopoulou P., Gribabis D.A., Kavantzas N., Angelopoulou M.K., Siakantaris M.P., Patsouris E., Androulaki A., Thymara I., Kokoris S.I., Kyrtsonis M.C., Kittas C. and Pangalis G.A. (2003a). A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. Br. J. Haematol. 122, 900-910.
58. Korkolopoulou P., Viniou N., Kavantzas N., Patsouris E., Thymara I., Pavlopoulos P.M., Terpos E., Stamatopoulos K., Plata E., Anargyrou K., Androulaki A., Davaris P. and Yataganas X. (2003b). Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia 17, 89-97.
59. Kumar S., Litzow M.R. and Rajkumar S.V. (2003). Effect of allogeneic stem cell transplantation on bone marrow angiogenesis in chronic myelogenous leukemia. Bone Marrow Transplant. 32, 1065-1069.
60. Kvasnicka H.M. and Thiele J. (1995). 3-dimensional reconstruction of serial sections in light microscopy. Pathologe 16, 128-138.
61. Kvasnicka H.M. and Thiele J. (2002). Quantification and morphometric analysis of vascular structures in the bone marrow. A critical review. Pathologe 23, 472-479.
62. Kvasnicka H.M., Thiele J., Amend T. and Fischer R. (1994). Three-dimensional reconstruction of histologic structures in human bone marrow from serial sections of trephine biopsies. Spatial appearance of sinusoidal vessels in primary (idiopathic) osteomyelofibrosis. Anal. Quant. Cytol. Histol. 16, 159-166.
63. Kvasnicka H.M., Thiele J., Staib P., Engels K., Kriener S. and Schmitt-Graeff A. (2004a). Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia. Pathologe 25, 127-134.
64. Kvasnicka H.M., Thiele J., Staib P., Schmitt-Graeff A., Griesshammer M., Klose J., Engels K. and Kriener S. (2004b). Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy. Blood 103, 3549-3551.
65. Le Bousse-Kerdiles M.C. and Martyre M.C. (1999a). Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia. Springer Semin. Immunopathol. 21, 491-508,
66. Le Bousse-Kerdiles M.C. and Martyre M.C. (1999b). Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann. Hematol. 78, 437-444.
67. Lisse I., Hasselbalch H. and Junker P. (1991). Bone marrow stroma in idiopathic myelofibrosis and other haematological diseases. An immunohistochemical study. APMIS 99, 171-178.
68. Little D., Said J.W., Siegel R.J., Fealy M. and Fishbein M.C. (1986). Endothelial cell markers in vascular neoplasms: an immunohistochemical study comparing factor VIII-related antigen, blood group specific antigens, 6-keto-PGF1 alpha, and Ulex europaeus 1 lectin. J. Pathol. 149, 89-95.
69. Lundberg L.G., Lerner R., Sundelin P., Rogers R., Folkman J. and Palmblad J. (2000). Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 157, 15-19.
70. Mandriota S.J. and Pepper M.S. (1997). Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 110, 2293-2302.
71. Mangi M.H. and Newland A.C. (2000). Angiogenesis and angiogenic mediators in haematological malignancies. Br. J. Haematol. 111, 43-51.
72. Martin L., Holcombe C., Green B., Leinster S.J. and Winstanley J. (1997). Is a histological section representative of whole tumour vascularity in breast cancer? Br. J. Cancer 76, 40-43.
73. McMahon G. (2000). VEGF receptor signaling in tumor angiogenesis. Oncologist 5 Suppl 1, 3-10.
74. Mesa R.A., Hanson C.A., Rajkumar S.V., Schroeder G. and Tefferi A. (2000). Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96, 3374-3380.
75. Mesa R.A., Hanson C.A., Li C.Y., Yoon S.Y., Rajkumar S.V., Schroeder G. and Tefferi A. (2002). Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-MpI expression in essential thrombocythemia. Blood 99, 4131-4137.
76. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W. and Ullrich A. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846.
77. Moehler T.M., Neben K., Ho A.D. and Goldschmidt H. (2001). Angiogenesis in hematologic malignancies. Ann. Hematol. 80, 695-705.
78. Murphy S. (1999). Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin. Hematol. 36, 9-13.
79. Murphy S., Peterson P., Iland H. and Laszlo J. (1997). Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin. Hematol. 34, 29-39.
80. Nagaoka T., Kuto F., Watanabe Y., Fujino Y., Hirasawa Y. and Tokuhiro H. (1986). Bone marrow sinus and cell egress in human leukaemia: a morphometric study of core biopsies using wide-field electron microscopy. Br. J. Haematol. 63, 737-747.
81. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R. and Druker B.J. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004.
82. Padro T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J., Buchner T., Berdel W.E. and Mesters R.M. (2000). Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95, 2637-2644.
83. Pavlopoulos P.M., Konstantinidou A.E., Agapitos E., Kavantzas N., Nikolopoulou P. and Davaris P. (1998). A morphometric study of neovascularization in colorectal carcinoma. Cancer 83, 2067-2075.
84. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E. and Folkman J. (1997). Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150, 815-821.
85. Piccaluga P.P., Visani G., Pileri S.A., Ascani S., Grafone T., Isidori A., Malagola M., Finelli C., Martinelli G., Ricci P., Baccarani M. and Tura S. (2002). Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 16, 1609-1614.
86. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., Ferrucci P.F., Buffa R., Lambertenghi-Deliliers G. and Pezzella F. (1999). Angiogenesis in myelodysplastic syndromes. Br. J. Cancer 81, 1398-1401.
87. Pruneri G., Ponzoni M., Ferreri AJ, Decarli N., Tresoldi M., Raggi F., Baldessari C., Freschi M., Baldini L., Goldaniga M., Ned A., Carboni N., Bertolini F. and Viale G. (2002). Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br. J. Haematol. 118, 817-820.
88. Pruneri G., Bertolini F., Baldini L., Valentini S., Goldaniga M., Soligo D., Carboni N., Viale G. and Lambertenghi-Deliliers G. (2003). Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. Br. J. Haematol. 120, 695-698.
89. Rafii S., Shapiro F., Pettengell R., Ferris B., Nachman R.L., Moore M.A. and Asch A.S. (1995). Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 86, 3353-3363.
90. Rafii S., Mohle R., Shapiro F., Frey B.M. and Moore M.A. (1997). Regulation of hematopoiesis by microvascular endothelium. Leuk. Lymphoma 27, 375-386.
91. Rajkumar S.V., Fonseca R., Witzig T.E., Gertz M.A. and Greipp P.R. (1999). Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 13, 469-472.
92. Rajkumar S.V. and Witzig T.E. (2000). A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev. 26, 351-362.
93. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., Dispenzieri A., Lacy M.Q., Lust J.A., Witzig T.E., Gertz M.A., Kyle R.A., Russell S.J. and Greipp P.R. (2002a). Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin. Cancer Res. 8, 2210-2216.
94. Rajkumar S.V., Mesa R.A. and Tefferi A. (2002b). A review of angiogenesis and anti-angiogenic therapy in hematologic malignancies. J. Hematother. Stem Cell Res. 11, 33-47.
95. Reilly J.T., Nash J.R., Mackie M.J. and McVerry B.A. (1985). Endothelial cell proliferation in myelofibrosis. Br. J. Haematol. 60, 625-630.
96. Ribatti D., Vacca A., Nico B., Quondamatteo F., Ria R., Minischetti M., Marzullo A., Herken R., Roncali L. and Dammacco F. (1999). Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer 79, 451-455.
97. Rumpel M., Friedrich T. and Deininger M.W. (2003). Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase. Blood 101, 4641-4643.
98. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., Kleinman H.K., Murphy W.J. and Oppenheim J.J. (1999). Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1 alpha. Am. J. Pathol. 154, 1125-1135.
99. Sezer O., Niemoller K., Kaufmann O., Eucker J., Jakob C., Zavrski I. and Possinger K. (2001). Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur. J. Haematol. 66, 238-244.
100. Silver R.T., Peterson B.L., Szatrowski T.P., Powell B.L., Stock W., Carroll A.J., Bloomfield C.D., Schiffer C.A. and Larson R.A. (2003). Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leuk. Lymphoma 44, 39-48.
101. Singhal S. and Mehta J. (2002). Thalidomide in cancer. Biomed. Pharmacother. 56, 4-12.
102. Stasi R. and Amadori S. (2002). The role of angiogenesis in hematologic malignancies. J. Hematother. Stem Cell Res. 11, 49-68.
103. Strupp C., Germing U., Aivado M., Misgeld E., Haas R. and Gattermann N. (2002). Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16, 1-6.
104. Tefferi A., Mesa R.A., Gray L.A., Steensma D.P., Camoriano J.K., Elliott M.A., Pardanani A., Ansell S.M., Call T.G., Colon-Otero G., Schroeder G., Hanson C.A., Dewald G.W. and Kaufmann S.H. (2002). Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 99, 3854-3856.
105. Thiele J. and Kvasnicka H.M. (2003a). Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features - a clinicopathological study on 272 patients. Histol. Histopathol. 18, 93-102.
106. Thiele J. and Kvasnicka H.M. (2003b). Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann. Hematol. 82, 148-152.
107. Thiele J., Hoeppner B., Zankovich R. and Fischer R. (1989). Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia) - correlations between clinical and morphological features. Virchows Arch. (A) 415, 191-202.
108. Thiele J., Rompcik V., Wagner S. and Fischer R. (1992). Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow. Br. J. Haematol. 80, 227-234.
109. Thiele J., Kvasnicka H.M., Amend T. and Fischer R. (1994). Megakaryocytes and sinus walls in primary osteomyelofibrosis: transendothelial migration as revealed by three-dimensional reconstruction of serial sections following sequential double-immunostaining. Virchows Arch. 424, 383-387.
110. Thiele J., Imbert M., Pierre R., Vardiman J.W., Brunning R.D. and Flandrin G. (2001a). Chronic idiopathic myelofibrosis. In WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S., Harris N.L., Stein H. and Vardiman J.W. (eds). IARC Press. Lyon. pp 35-38.
111. Thiele J., Kvasnicka H.M., Beelen D.W., Leder L.D. and Schaefer U.W. (2001 b). Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients. Histol. Histopathol. 16, 213-226.
112. Thiele J. and Kvasnicka H.M. (2002). CD34+ stem cells in chronic myeloproliferative disorders. Histol. Histopathol. 17, 507-521.
113. Thomas D.A. and Kantarjian H.M. (2000). Current role of thalidomide in cancer treatment. Curr. Opin. Oncol. 12, 564-573.
114. Thomas D.A., Giles F.J., Cortes J., Albitar M. and Kantarjian H.M. (2001). Antiangiogenic therapy in leukemia. Acta Haematol. 106, 190-207.
115. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F. and Dammacco F. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol. 87, 503-508.
116. Vacca A., Ribatti D., Roccaro A.M., Ria R., Palermo L. and Dammacco F. (2001). Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol. 106, 162-169.
117. Van Dyke D., Parker H., Anger H.O., McRae J., Dobson E.L., Yano Y., Naets J.P. and Linfoot J. (1971). Markedly increased bone blood flow in myelofibrosis. J. Nucl. Med. 12, 506-512.
118. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P., Pezzella F., Viale G., Weidner N., Harris A.L. and Dirix L.Y. (1996). Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A, 2474-2484.
119. Verstovsek S., Kantarjian H., Manshouri T., Cortes J., Giles F.J., Rogers A. and Albitar M. (2002a). Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 99, 2265-2267.
120. Verstovsek S., Kantarjian H., Manshouri T., O'Brien S., Faderl S., Talpaz M., Corles J. and Albitar M. (2002b). Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia. Cancer 94, 1517-1521.
121. Weidner N. (1999). Tumour vascularity and proliferation: clear evidence of a close relationship. J. Pathol. 189, 297-299.
122. Weidner N., Semple J.P., Welch W.R. and Folkman J. (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8.
123. Weidner N., Carroll P.R., Flax J., Blumenfeld W. and Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143, 401-409.
124. Wimazal F., Jordan J.H., Sperr W.R., Chott A., Dabbass S., Lechner K., Horny H.P. and Valent P. (2002). Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am. J. Pathol. 160, 1639-1645.
125. Wolf B.C. and Neiman R.S. (1985). Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 65, 803-809.
126. Zorat F. and Pozzato G. (2002). Thalidomide in myelodysplastic syndromes. Biomed. Pharmacother. 56, 20-30.